The Iowa Oncology Research Association (IORA) is a multidisciplinary consortium of nine Iowa hospitals, fourteen surgical, medical and radiation oncology practices and 68 physicians. Six of the hospitals are located in Des Moines, one in Ames, one in Mason City and one in Ottumwa. The IORA has been a principal member of North Central Cancer Treatment Group (NCCTG) since 1979 and has secondary research bases with Eastern Cooperative Oncology Group (ECOG), National Surgical Adjuvant Breast and Bowel Project (NSABP) and Children's Oncology Group (COG). The IORA also actively participates in Cancer Trials Support Unit (CTSU) and Southwest Oncology Group (SWOG) prostate cancer prevention trials. The goals of IORA are: 1) Provide excellence in cancer care to patients and families through participation in high quality cancer research;2) Increase participation in adult and pediatric cancer treatment and cancer control clinical trials. Several steps have been or will be implemented to accomplish this goal for the adult population. The primary change centers on the re-organization of the Des Moines staff with one CRA to be on site at two of the medical oncology offices. This arrangement will foster a more collaborative working relationship and generate significantly more referrals for both cancer treatment and cancer control studies;3) Support the goals and work of research bases with involvement of IORA investigators and patient populations;4) Increase public and professional awareness of clinical trials through community outreach efforts and collaboration with other medical providers in the community;5) Increase community participation in prevention studies such as the upcoming NSABP P-4 Breast Cancer Prevention Study by building on successful recruitment and retention strategies implemented in previous cancer prevention studies;6) Develop strategies to increase minority involvement in cancer research. IORA investigators will continue to offer treatment studies to their minority patient population, keeping in mind that Iowa is 95% Caucasian. For cancer prevention trials, this goal will be accomplished through collaboration with local minority advocacy groups and health care institutions with high minority patient populations. The IORA has a proven track record as an efficient and disciplined team from four strategically located Iowa communities. The organization is the link between clinical trials and a significant portion of the state of Iowa with a catchment area that includes 48 counties and 43% of the state's population. The IORA will continue to enthusiastically emphasize quality in its research efforts and actively pursue accrual.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035101-25
Application #
7844988
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
O'Mara, Ann M
Project Start
1995-06-01
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
25
Fiscal Year
2010
Total Cost
$685,544
Indirect Cost
Name
Iowa Oncology Research Association
Department
Type
DUNS #
180870891
City
Des Moines
State
IA
Country
United States
Zip Code
50309
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83

Showing the most recent 10 out of 160 publications